Shionogi to Acquire Tetra Therapeutics for ~$500M

 Shionogi to Acquire Tetra Therapeutics for ~$500M

Shionogi to Acquire Tetra Therapeutics for ~$500M


  • Shionogi to acquire Tetra for a total value of up to $500M which includes regulatory and commercial milestones, based on certain achievements. Following the acquisition, Shionogi will get global rights to Tetra’s portfolio for CNS disorders including BPN14770
  • In 2018, the two companies collaborated and in 2020 expand their alliance to develop and commercialize BPN14770 for AD, FXS, and other indications. Additionally, Tetra is evaluating BPN14770 in a P-II study for FXS and has completed a P-II study for AD in the US
  • BPN14770 is a selective inhibitor of phosphodiesterase-4D, having a potential to improve cognitive and memory function in CNS disorders and has received the US FDA’s ODD for FXS

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: StraitTimes

Related News: Tetra Therapeutics and Shionogi Expand their Existing 2018 Collaboration to Develop and Commercialize BPN14770

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on

Related post